Abbisko Units Gets China Clearance for Lung Cancer Drug Application; Shares Jump 3%
MT Newswires Live
Aug 21
Abbisko (HKG:2256) unit Abbisko Therapeutics obtained clearance for the investigational new drug application of ABSK043 from China's National Medical Products Administration, a same-day Hong Kong bourse filing said.
Shares of the biopharmaceutical firm were up 3% in Thursday afternoon trading.
The clearance is for the drug in combination with Shanghai Allist Pharmaceuticals' glecirasib for the treatment of patients with non-small cell lung cancer.
The two companies had entered into a cooperation agreement In March to explore the said combination of drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.